Byomass Inc.
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Website
- byomasstx.com
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Sbir topic 395: identification of BI-specific antibodies to inhibit GDF-15 and activin a for anorexia-cachexia | National Cancer Institute (NIH) | $299,871 |
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Kibio Inc. | Davis, CA | — |
| Microquin LTD | Cambridge, MA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Modulo Bio, Inc. | San Diego, CA | — |
| Institute Of Cancer Research: Royal Cancer Hospital (The) | England | — |
| Atux Iskay Group LLC | Plainsboro Township, NJ | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
About the company
Byomass Inc., a for-profit biomedical research organization based in Sudbury, Massachusetts, acts as a federal grant recipient, developing novel therapeutic candidates for cancer, mental health, and related conditions under awards from the Defense Health Agency and the National Institutes of Health. The company operates entirely as a prime recipient (100% of recent awards) with no federal contracting footprint and no subcontracting relationships in the federal space.
Byomass's capability portfolio centers on antibody development and small-molecule drug discovery for oncology and psychiatric therapeutic indications. The company's recent federal grant work includes a $3.04 million Defense Health Agency project grant (CFDA 12.420, Military Medical Research and Development program) awarded June 15, 2026, funding four-year preclinical and clinical development of BYOM-1022, a novel therapeutic for anxiety, depression, and suicidal ideation associated with hyperemesis gravidarum, with completion expected June 14, 2030. Prior grants include a $694,935 Defense Health Agency award (November 1, 2025) supporting two-year development of BYOM-1119 for prevention and treatment of pancreatic cancer metastases and cachexia, and a $1.383586 million Defense Health Agency grant (February 15, 2024) funding three-year development of BYOM-0322, a biologic agent targeting TGF-beta superfamily for breast cancer metastases and cancer cachexia prevention and treatment.
All recent federal funding flows from two agencies: the Defense Health Agency (three awards, status and dollar value not disaggregated in source) and the National Institutes of Health National Cancer Institute (two awards, $355,000 combined potential value). The company's federal grant activity spans two decades with a gap pattern — two awards in 2019, then no federal activity until 2024 — suggesting recent acceleration in federal grant capture. One award reaches ultimate completion within the next twenty-four months, presenting a recompete opportunity in that window.
</final_answer>
Quick answers
Is Byomass Inc. registered in SAM.gov?
Byomass Inc.'s SAM.gov registration expired on October 28, 2026.
What is Byomass Inc.'s CAGE code?
Byomass Inc.'s CAGE code is 7ZM19, and its Unique Entity ID (UEI) is N57BMT7GFJG6.
What is Byomass Inc.'s most recent federal award?
Byomass Inc.'s most recent federal grant award is Development of byom-1022 for the treatment of hyperemesis gravidarum-induced anxiety, depression and suicidal tendencies (HT9425261E228), from Defense Health Agency, on June 15, 2026.
On GovTribe
See Byomass Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors